ArticleBMC psychiatry2026
Graph Neural Networks and sequential architectures for autism detection from eye-tracking biomarkers: a multi-site study.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutism Spectrum Disorder (ASD) affects 1 in 100 children globally, yet early detection remains challenging due to reliance on subjective behavioral assessments and limited specialist availability, particularly in resource-constrained settings. Eye-tracking biomarkers offer objective, quantitative measurements of visual attention patterns, but existing Neural Network approaches lack systematic evaluation across diverse neural network architectures and multi-site data. This study provides a comprehensive comparison of Graph Neural Networks, Long Short-Term Memory networks, and Multilayer Perceptrons for ASD detection using multimodal eye-tracking features.
methodsWe combined two independent datasets: CILIA (57 participants from France, structured viewing paradigm) and Saliency4ASD (27 participants from Italy, free-viewing paradigm), creating a diverse multi-site European cohort of 84 participants (40 ASD, 44 typically developing). Four neural network architectures were evaluated: Graph Neural Networks (GNNs) with attention mechanisms, GNN without attention, bidirectional Long Short-Term Memory (LSTM), and Multi-Layer Perceptron (MLP) networks. Eye-tracking features included fixation patterns, saccade dynamics, pupil diameter, and spatial attention distributions. Leave-one-subject-out cross-validation ensured robust generalization. Statistical comparisons employed DeLong tests for area under the ROC curve differences, McNemar tests for accuracy, and bootstrap confidence intervals (10,000 iterations). Per-dataset performance analysis assessed generalization across acquisition protocols.
resultsLSTM achieved the highest AUC of 0.859 (95% CI: 0.770-0.934), followed by GNN with attention (AUC = 0.855, 95% CI: 0.763-0.931). Contrary to expectations, attention mechanisms did not significantly improve GNN performance (GNN without attention: AUC = 0.823, p = 0.102). LSTM significantly outperformed MLP (AUC = 0.811, p = 0.002) but showed no significant difference versus GNN with attention (p = 0.749). GNN with attention demonstrated the highest specificity (93.2%) and positive predictive value (90.6%). Performance remained consistent across both datasets (LSTM: AUC = 0.840 on CILIA versus 0.956 on Saliency4ASD), supporting generalization across datasets despite different viewing paradigms, equipment, and cultural populations. All models exhibited large effect sizes (Cohen's d exceeding 1.0) for discriminating ASD from typically developing predictions.
conclusionsThis systematic evaluation demonstrates that LSTM and graph-based approaches achieve equivalent performance for ASD detection from eye-tracking biomarkers, with attention mechanisms providing no significant benefit. The high specificity (93.2%), real-time capability, and cross-dataset generalization make these models viable for scalable, objective ASD screening in clinical settings, potentially enabling earlier intervention in resource-constrained environments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.